Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Haleos Labs Ltd (HALEOSLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540679 NSE: HALEOSLABS Pharmaceuticals & Drugs | Small Cap | Haleos Labs Share Price

₹1,498.65 29.70 (2.02%)

As on 25-Sep'26 16:59

Haleos Labs Ltd (HALEOSLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540679 NSE: HALEOSLABS Pharmaceuticals & Drugs | Small Cap | Haleos Labs Share Price

₹1,498.65 29.70 (2.02%)

As on 25-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹453 Cr.
Current Price
₹1,498.7
52-Week Low / High
₹1,101 / 1,778
TTM EPS
₹52.3
TTM Sales
₹324 Cr.
Book Value per Share
₹712.4
P/E Ratio
28.67
Higher than its 5-year historical median
Industry PE
54.9
Price to Book (P/B)
2.10
Higher than its 5-year historical median
Price to Sales (P/S)
1.40
Higher than its 5-year historical median
EV/EBITDA
12.72
Higher than its 5-year historical median
Dividend Yield
0.1%
Profitability Efficiency
Return on Equity (ROE)
10.03%
Outperforms industry median
Return on Capital Employed (ROCE)
12.60%
Outperforms industry median
Return on Assets (ROA)
4.72%
Operating Profit Margin
13.1%
Net Profit Margin
5.43%
Gross Profit Margin
10.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
11.12%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
44.46%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
195.89%
Asset Quality
Promoter Holding
72.11%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹212 Cr.
Equity
₹3 Cr.
Face Value
₹10
All Time Low / High
₹134.85 / 1778.35

Haleos Labs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Haleos Labs Ltd a good quality company?
Haleos Labs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Haleos Labs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Haleos Labs Ltd vs industry peers?
Haleos Labs Ltd revenue CAGR is 5.74%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Haleos Labs Ltd?
Promoters hold 72.11% of the Haleos Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Haleos Labs Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 16.03% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Haleos Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ0%45.7%9.5%21.8%11.7%14.4%19.7%10.2%10.9%14%-
Value Creation
Index ⓘ		NA2.3-0.30.6-0.20.00.4-0.3-0.20-

Growth Parameters ⓘ
Sales ⓘ0216213344257260346315300333290
Sales YoY Gr.-NA-1.3%61.6%-25.4%1.3%32.8%-8.8%-4.8%11.1%-
Adj EPS ⓘ-1.912,173.416.450.727.141.45237.538.86752.5
YoY Gr.-NA-99.9%209.7%-46.5%52.6%25.7%-27.8%3.5%72.7%-
BVPS (₹) ⓘ-8.281,838.7292.4347.2374.6417.9500.2542.6582.9652.2720.5
Adj Net
Profit ⓘ		-012.2515.38.212.515.711.411.720.316
Cash Flow from Ops. ⓘ019.7827.31421.6-14.74.614.828-
Debt/CF from Ops. ⓘ01.33.41.73.52.1-4.118.662.8-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNA5.4%-1.2%11.1%
Adj EPS ⓘNA19.8%8.8%72.7%
BVPSⓘNA11.7%9.3%11.9%
Share Price - 16.3% 43% 30.9%

Key Financial Parameters ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		-67.529.85.815.87.510.511.37.26.910.97.6
Op. Profit
Mgn % ⓘ		013.26.29.59.311.59.18.411.513.313.2
Net Profit
Mgn % ⓘ		05.62.34.53.24.84.63.63.96.15.5
Debt to
Equity ⓘ		-0.40.30.30.50.40.40.40.50.50.4-
Working Cap
Days ⓘ		085158114159155150182199186112
Cash Conv.
Cycle ⓘ		013371923282446686332

Valuation of Haleos Labs - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales378261266350316306345
Operating Expenses ⓘ + 343235235316287275300
Manufacturing Costs51415166575967
Material Costs256158137195171151154
Employee Cost 23273140435260
Other Costs ⓘ 13101715141319
Operating Profit ⓘ 35253035293145
Operating Profit Margin (%) 9.2%9.7%11.4%9.9%9.1%10.2%13.1%
Other Income ⓘ + 3222345
Exceptional Items ⓘ 00013200
Interest ⓘ 65567109
Depreciation ⓘ 68810111515
Profit Before Tax ⓘ 25152033171026
Tax ⓘ 8467547
Profit After Tax 1810142511619
PAT Margin (%) 4.7%3.9%5.1%7.2%3.6%2.1%5.4%
Adjusted EPS (₹)59.033.744.883.837.930.166.5
Dividend Payout Ratio (%)2.50%0%3.40%1.80%4%5%2.30%
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 106116129152169177197
Share Capital ⓘ 3.023.023.023.023.023.023.02
Reserves ⓘ 103113126149166174194
Debt +40585967858069
Long Term Debt27373940553318
Short Term Debt13212027304750
Minority Interest00013201715
Trade Payables98496778605953
Others Liabilities ⓘ 32335154656265
Total Liabilities ⓘ 276256307364398395399

Fixed Assets

Net Fixed Assets ⓘ +117124130142228223232
Gross Block136150164177281290312
Accumulated Depreciation18253435526680
CWIP ⓘ 3163851160
Investments ⓘ 0000000
Inventories81646285868167
Trade Receivables41223434465169
Cash Equivalents 38114412
Others Assets ⓘ 31223248323129
Total Assets ⓘ 276256307364398395399
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 301535-11152434
PBT ⓘ 25152020141026
Adjustment ⓘ 9111014162125
Changes in Working Capital ⓘ 2-810-38-12-4-8
Tax Paid ⓘ -7-3-5-8-3-3-9
Cash Flow From Investing Activity ⓘ + -44-27-26-7-31-18-15
Capex -24-23-29-42-43-21-15
Net Investments -20-4334112-0
Others ⓘ 0000000
Cash Flow From Financing Activity ⓘ + 1512-31117-7-19
Net Proceeds from Shares ⓘ 0000000
Net Proceeds from Borrowing ⓘ 1381420-14-17
Interest Paid ⓘ -2-3-3-4-4-6-4
Dividend Paid ⓘ -1-10-0-0-0-0
Others ⓘ 68-1101143
Net Cash Flow ⓘ 1-06-80-1-0
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)16.799.1711.0717.987.093.6610.03
ROCE (%)20.1411.9112.9618.429.457.4212.6
Asset Turnover Ratio1.511.091.051.160.940.850.97
PAT to CFO Conversion(x)1.671.52.5-0.441.3641.79
Working Capital Days
Receivable Days36.2039.5034.5031.9040.7052.4056.80
Inventory Days71.1091.4077.9068.8087.2090.1070.30
Payable Days139.70169.90154.60135.90146.50143.40133.20

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Haleos Labs Ltd FAQs

The current trading price of Haleos Labs on 25-Sep-2026 16:59 is ₹1,498.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of Haleos Labs stood at ₹453.1 Cr

The latest P/E ratio of Haleos Labs as of 24-Sep-2026 is 28.57.

The latest P/B ratio of Haleos Labs as of 24-Sep-2026 is 2.08.

The 52-week high of Haleos Labs is ₹1,778.4 and the 52-week low is ₹1,100.6.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Haleos Labs is ₹290 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Haleos Labs Ltd is a below average quality company.

The key valuation ratios of Haleos Labs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Haleos Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Haleos Labs Ltd

No data to display
You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now